At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET
Denali Therapeutics reported Q3 2026 AVLAYAH net product revenue of $17.8M, its second full commercial quarter, and guided Q4 2026 revenue to $30.0M-$32.0M. Net income of $70.1M included a one-time $194.0M gain on sale of a Priority Review Voucher, while operating loss was $126.8M. Cash and securities totaled $1.0B.
- AVLAYAH net product revenue $17.8M in Q3 2026 (second full commercial quarter).
- Q4 2026 net product revenue guidance of $30.0M-$32.0M.
- Net income $70.1M vs net loss $126.9M in Q3 2025; includes $194.0M one-time gain on sale of Priority Review Voucher.
- Operating loss $126.8M vs $137.4M in Q3 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access